Inside Life Sciences Issue 13: April 2021 Post Editor's Note Welcome to the Spring edition of Inside Life Sciences. News Lundbeck 'pay for delay' case: CJEU judgment As anticipated, the CJEU has upheld the General Court's judgment that patent settlement agreements between Lundbeck and several generic manufacturers were a restriction of competition by object. News Patents Court applies Supreme Court's Regeneron sufficiency principles In Illumina v Latvia MGI Tech, the Patents Court has applied for the first time the Supreme Court's decision relating to sufficiency in Regeneron. News Patents Court reverses orders in Neurim v Mylan case following EPO revocation The Patents Court has considered the interplay between the twin tracks of UK and EPO revocation proceedings in the assessment of remedies. News Aspen's excessive pricing case concludes with commitments The European Commission has announced it has agreed to accept commitments following its investigation into pricing practices. News Teva's divisional patent strategy under the Commission spotlight In March 2021, the European Commission announced it had opened a formal competition investigation in relation to Teva's divisional patent strategy concerning Copaxone. News Patents Court finds ostomy bag patent invalid for lack of inventive step The Patents Court has found a patent relating to ostomy bags invalid as obvious over the common general knowledge, as well as five pieces of prior art. News UK Government considers legislative exemption for CBD consumer products The Government has revealed that it is considering introducing a new exemption for cannabidiol (CBD) consumer products under the Misuse of Drugs Regulations 2001. News FSA publishes list of just three permitted CBD companies The Food Standards Agency (FSA) has published its list of the CBD products which can lawfully remain on sale to consumers pending the FSA's formal authorisation. The list contains 22 products only, from just three CBD companies. News Patents Court considers 'sequential unmasking' approach to expert evidence The Patents Court has considered the approach to adopt when instructing expert witnesses and, in particular, the sequence in which they are shown documents. News Competition authorities join forces to consider approach to pharma mergers Competition authorities in the UK, EU, US and Canada have joined forces to form a working group dedicated to issues around mergers in the pharmaceutical sector. News Pharmaceutical companies granted permission to appeal ruling that regulators should not pay costs of a successful appeal against a decision The Supreme Court has granted permission to Flynn Pharma and Pfizer to appeal the Court of Appeal ruling that required them to pay the costs of their successful appeal against a Competition and Markets Authority decision. News New Investment for Life Sciences in the UK With the life sciences sector contributing more than £70bn per year to the UK economy, the UK Government has proposed a new public/private investment fund into the sector. News The Medicines and Medical Devices Act 2021: A framework for updating the UK life sciences regime The Medicines and Medical Devices Act 2021 (MMDA) received Royal Assent on 11 February 2021. The context for the MMDA is that much of the legal and regulatory framework for medicines and medical devices derives from EU Directives. Previous Issues Next Issue 13 Apr 2021 Issue 12 Nov 2020 Issue 11 Aug 2020 Issue 10 Jun 2020 Issue 9 Dec 2019 Issue 8 Jul 2019 Issue 7 Mar 2019 Issue 6 Nov 2018 Issue 5 Jul 2018 Issue 4 Mar 2018 Issue 3 Nov 2017 Share
News Lundbeck 'pay for delay' case: CJEU judgment As anticipated, the CJEU has upheld the General Court's judgment that patent settlement agreements between Lundbeck and several generic manufacturers were a restriction of competition by object.
News Patents Court applies Supreme Court's Regeneron sufficiency principles In Illumina v Latvia MGI Tech, the Patents Court has applied for the first time the Supreme Court's decision relating to sufficiency in Regeneron.
News Patents Court reverses orders in Neurim v Mylan case following EPO revocation The Patents Court has considered the interplay between the twin tracks of UK and EPO revocation proceedings in the assessment of remedies.
News Aspen's excessive pricing case concludes with commitments The European Commission has announced it has agreed to accept commitments following its investigation into pricing practices.
News Teva's divisional patent strategy under the Commission spotlight In March 2021, the European Commission announced it had opened a formal competition investigation in relation to Teva's divisional patent strategy concerning Copaxone.
News Patents Court finds ostomy bag patent invalid for lack of inventive step The Patents Court has found a patent relating to ostomy bags invalid as obvious over the common general knowledge, as well as five pieces of prior art.
News UK Government considers legislative exemption for CBD consumer products The Government has revealed that it is considering introducing a new exemption for cannabidiol (CBD) consumer products under the Misuse of Drugs Regulations 2001.
News FSA publishes list of just three permitted CBD companies The Food Standards Agency (FSA) has published its list of the CBD products which can lawfully remain on sale to consumers pending the FSA's formal authorisation. The list contains 22 products only, from just three CBD companies.
News Patents Court considers 'sequential unmasking' approach to expert evidence The Patents Court has considered the approach to adopt when instructing expert witnesses and, in particular, the sequence in which they are shown documents.
News Competition authorities join forces to consider approach to pharma mergers Competition authorities in the UK, EU, US and Canada have joined forces to form a working group dedicated to issues around mergers in the pharmaceutical sector.
News Pharmaceutical companies granted permission to appeal ruling that regulators should not pay costs of a successful appeal against a decision The Supreme Court has granted permission to Flynn Pharma and Pfizer to appeal the Court of Appeal ruling that required them to pay the costs of their successful appeal against a Competition and Markets Authority decision.
News New Investment for Life Sciences in the UK With the life sciences sector contributing more than £70bn per year to the UK economy, the UK Government has proposed a new public/private investment fund into the sector.
News The Medicines and Medical Devices Act 2021: A framework for updating the UK life sciences regime The Medicines and Medical Devices Act 2021 (MMDA) received Royal Assent on 11 February 2021. The context for the MMDA is that much of the legal and regulatory framework for medicines and medical devices derives from EU Directives.